The panel will also vote on whether to delay the hepatitis B birth dose until at least one month of age or leave it up to shared decision-making with parents unless the mother tests positive for the virus. But many public health experts warn the changes could reverse decades of progress against infectious disease. "The U.S. didn't make much progress in combating hepatitis B until they moved to the birth dose," said Noel Brewer, a former ACIP member who was dismissed in the committee shakeup. The changes come after the firing of former CDC Director Susan Monarez, who told Congress she was pressured to rubber-stamp Kennedy's agenda. Dr. Jesse Goodman, former chief scientist at the FDA, said the hepatitis B vote in particular poses a public health risk.